期刊文献+

丹田降脂丸治疗高脂血症临床观察 被引量:6

Clinical observation on treating hyperlipidemia with the pubic region lipid-lowering pills
下载PDF
导出
摘要 目的:比较丹田降脂丸与辛伐他汀治疗高脂血症的临床疗效。方法:将70例患者随机分为治疗组35例,对照组35例。治疗组服用丹田降脂丸1g,2次/d。对照组服用辛伐他汀片20mg,每晚1次。两组疗程均为2月。结果:两组TC、TG、HPL-C、LDL-C自身治疗前后比较差异有统计学意义(P<0.01),两组治疗后比较(P>0.05)差异无统计学意义。临床总有效率比较(P>0.05)无统计学差异。结论:丹田降脂丸治疗高脂血症与他汀类药物比较,除具有较好的调脂作用外,还有扩张冠状动脉,改善心肌缺血,改善微循环,降血压作用,特别适用于合并心脑血管疾病的患者。 Objective: Comparing the clinical effects of pubic region lipid-lowering pills and simvastatin in treating hyperlipidemia. Methods: 70 cases were randomly divided into the treatment group (35 cases) and the control group (35 cases). The treatment group taken the pubic region lipid-lowering pills lg, 2 times/d. The control group was given simvastatin 20rag per night 1. The two groups of treatment lasted two months. Results: Two groups of the TC, TG and of HPL-C, LDL-C before and after treatment the difference was statistically significant (P〈0.01). After treatment, the difference was not statistically significant (P〉0.05). The total clinical effective rate was no significant difference (P〉O.05). Conclusion: Compared with statins, pubic region lipid-lowering pills in treating hyperlipidemia, in addition to a better lipid mechanisms, as well as expansion of the coronary arteries, improving myocardial ischemia, improving microcirculation, blood pressure lowering effect, especially suitable for patients with cardiovascular and cerebrovascular diseases.
出处 《中医临床研究》 2012年第16期15-16,共2页 Clinical Journal Of Chinese Medicine
关键词 高脂血症 丹田降脂丸 心脑血管疾病 辛伐他汀 Hyperlipidemia Pubic region lipid-lowering pills Cardiovascular and cerebrovascular diseases Simvastatin
  • 相关文献

参考文献4

二级参考文献21

  • 1Pisehon T. Use of obesity bionmrkers in cardiovascular epidemiology [ J]. Dis Markers, 2009, 26 (5-6): 247-263.
  • 2Xu HB, Huang ZQ. Vasorelaxant effects of icariin on isolated canine coro- nary artery [ J ]. J Cardiovogic Pharmacol, 2007, 49 (4): 207-213.
  • 3Xu HB, Huang ZQ. Icariin enhances endothelial nitric-oxide synthase ex- pression on human endothelial cells in vitro [ J ]. Vascul Pharmacol, 2007, 47 ( 1 ) : 18-24.
  • 4Alipour A, Elte JW, van-Zaanen HC, et al. Novel aspects of postprandial lipemia in relation to atherosclerosis [ J ]. Atheroscler Suppl, 2008, 9 (2) : 39-44.
  • 5Kerenyi L, Mihalka L, Csiba L, et al. Role of hyperlipidemia in atherosclerotic plaque formation in the internal carotid artery [J]. J Clin Ultrasound, 2006, 34 (6) : 283-288.
  • 6Scherer PE, W illiams S, Fogliano M, et al. A novel serum protein similar to Clq, produced exclusively in adipocytes [ J]. J Biol Chem, 1995, 270 (45) : 26 746-749.
  • 7Zyriax BC, Algenstaedt P, Hess UF, et al. Factors contributing to the risk of cardiovascular disease reflected by plasma adiponectin data from the corenary risk factors for atheresclerosis in women (CORA) study [ J ]. Atherosclerosis, 2008, 200 (2) : 403-409.
  • 8Liping Q, Chenhui Z, Deneys RW, et al. Adiponectin reduces plasma triglyceride by increasing VLDL triglyceride catabolism [ J ]. Diabetes, 2008, 57 (7) : 1 824-833.
  • 9Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antldiabetic metabolic effects [ J ]. Nature, 2003, 423 (6941) : 762-769.
  • 10Li R, Xu M, Wang X. Reduced vascular responsiveness to adiponectin in hypertipidemic rats-mechanisms and significance [ J ]. J Mol Cell Cardiol, 2010, 49 (4) : 576-578.

共引文献116

同被引文献68

引证文献6

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部